^a Tested in dextrose 5%.

^b Tested in sodium chloride 0.9%.

^c Tested in both dextrose 5% and sodium chloride 0.9%.

^d Tested in Ringer’s injection, lactated.

^e Tested in sodium chloride 0.45%.

^f Tested in dextrose 5% with albumin human 2 mg/mL.

^g Lyophilized formulation tested.

^h Refer to Appendix for the composition of parenteral nutrition solutions. TNA indicates a 3-in-1 admixture, and TPN indicates a 2-in-1 admixture.

ⁱ Run at 21 mL/hr.

^j Given over 30 minutes by syringe pump.

^k Run at 94 mL/hr.

^l Run at 10 mL/hr.

^m Given over one hour by syringe pump.

ⁿ Tested in sterile water for injection.

^o Injected via Y-site into an administration set running azithromycin.

^p Piperacillin component. Piperacillin in an 8:1 fixed-ratio concentration with tazobactam.

^q Test performed using the formulation WITH edetate disodium.

^r Test performed using the formulation WITHOUT edetate disodium.

^s Ceftolozane component. Ceftolozane in a 2:1 fixed-ratio concentration with tazobactam.

^t Meropenem component. Meropenem in a 1:1 fixed-ratio concentration with vaborbactam.

^u Ceftazidime component. Ceftazidime in a 4:1 fixed-ratio concentration with avibactam.

^v Tested in dextrose 5%, sodium chloride 0.9%, and Ringer’s injection, lactated.

^w Salt not specified.

^x Imipenem component. Imipenem in a 2:2:1 fixed-ratio concentration with cilastatin and relebactam.

^y Sulbactam component. Sulbactam in a 1:1 fixed-ratio concentration with durlobactam.